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studyquestion:Will the use of levonorgestrel (LNG) 1.5 mg taken at each dayof coitus bywomenwho have relatively infrequent sex be
an efﬁcacious, safe and acceptable contraceptive method?
summary answer: Typical use of LNG 1.5 mg taken pericoitally, before or within 24 h of sexual intercourse, provides contraceptive
efﬁcacy of up to 11.0 pregnancies per 100 women-years (W-Y) in the primary evaluable population and 7.1 pregnancies per 100 W-Y in the
evaluable population.
what is knownalready: LNG1.5 mg is an effective emergency contraception following unprotected intercourse. Some users take it
repeatedly, as their means of regular contraception.
studydesign, size, duration: Thiswas a prospective, open-label, single-arm,multicentrePhase III trial studywithwomenwhohave
infrequent coitus (onup to6days amonth). Eachwomanhada follow-up visit at 2.5, 4.5 and6.5months after admissionor until pregnancyoccurs if
sooner, or she decided to interrupt participation. The study was conducted between 10 January 2012 and 15 November 2014.
participants/materials, setting, methods: A total of 330 healthy fertile women aged 18–45 years at risk of pregnancy
who reported sexual intercourse on up to 6 days a month, were recruited from four university centres located in Bangkok, Thailand; Campinas,
Brazil; Singapore and Szeged, Hungary to use LNG 1.5 mg pericoitally (24 h before or after coitus) as their primary method of contraception.
The participants were instructed to take one tablet every day she had sex, without taking more than one tablet in any 24-h period, and to
maintain a paper diary for recording date and time for every coital act and ingestion of the study tablet, use of other contraceptive
methods and vaginal bleeding patterns. Anaemia was assessed by haemoglobin evaluation. Pregnancy tests were performed monthly and preg-
nancies occurring during product use were assessed by ultrasound. At the 2.5-month and ﬁnal visit at 6.5 months, acceptability questions were
administered.
main results and the role of chance: There were 321 women included in the evaluable population (which includes all
eligible women enrolled), with 141.9 woman-years (W-Y) of observation and with a rate (95% conﬁdence interval [CI]) of 7.1 (3.8; 13.1)
pregnancies per 100 W-Y of typical use (which reﬂects use of the study drug as main contraceptive method, but also includes possible use
of other contraceptives from admission to end of study) and 7.5 (4.0; 13.9) pregnancies per 100 W-Y of sole use. In the primary evaluable
& The Author 2016. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology.
This is anOpen Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits
non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
Human Reproduction, Vol.31, No.3 pp. 530–540, 2016
doi:10.1093/humrep/dev341
population (which includes only eligible enrolled women ,35 years old), the rate was 10.3 (5.4; 19.9) pregnancies per 100W-Y of typical use,
and 11.0 (5.7; 13.1) pregnancies per 100 W-Y of sole use. There were three reported severe adverse events and 102 other mild adverse
events (most common were headache, nausea, abdominal and pelvic pain), with high recovery rate. The vaginal bleeding patterns showed
a slight decrease in volume of bleeding and the number of bleeding-free days increased over time. There was only one case of severe
anaemia, found at the ﬁnal visit (0.4%). The method was considered acceptable, as over 90% of participants would choose to use it in the
future or would recommend it to others.
limitations, reasons for caution: This was a single-arm study with small sample size, without a control group, designed as a
proof of concept study to explore the feasibility of this type of contraception.
wider implications of the findings: A larger clinical study evaluating pericoital contraception with LNG is feasible and our
data show that this method would be acceptable to many women.
study funding/competing interest(s): This study received partial ﬁnancial support from the UNDP/UNFPA/UNICEF/
WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP), Department of
Reproductive Health and Research (RHR) and the World Health Organization. Gynuity and the Bill and Melinda Gates Foundation
(BMGF) provided ﬁnancial support for project monitoring. HRA Pharma donated the LNG product. N.K. was the initial project manager
when she was with WHO/HRP and was employed by HRA Pharma, which distributes LNG for emergency contraception. The other
authors declare no conﬂicts of interest.
trial registration number: This study was registered on ANZCTR, Trial ID ACTRN12611001037998.
trial registration date: 4 October 2011.
date of first patient’s enrolment: 10 January 2012.
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Introduction
Recent survey data and anecdotal information from sources in Africa,
Latin America, Europe, and the USA suggested that many women are
interested in an oral contraceptive pill (OCP) that is designed to be
used only at the time of sexual intercourse (Arowojolu and Adekunle,
2000; Lerkiatbundit and Reanmongkol, 2000; Gilliam et al., 2009;
Taylor et al., 2014). Such a method may have numerous advantages
over daily OCP for women who have infrequent sex. For some
women, taking an OCP only when needed may seem more intuitive
than taking one every day even when sex has not occurred.
Users may ﬁnd compliance easier with a coital-dependent pill regimen
because pill-taking is triggered by a deﬁned event and does not necessitate
advance planning or routine intake. For most women, a coital-dependent
pill regimen would require fewer doses than a daily pill regimen and
would be more convenient. Furthermore, unlike other coital-dependent
methods, such as condoms, diaphragms and spermicides, a contraceptive
pill takenorally has thepotential tobeusedwithout the cooperationor the
knowledge of the male partner.
Levonorgestrel (LNG) when taken post-coitally has been studied ex-
tensively as amethodof emergency contraception (EC) and the principal
mechanismof action is to arrest or delayovulation (Croxatto et al., 2001,
2004; Marions et al., 2002, 2004; Gemzell-Danielsson and Marions,
2004; Okewole et al., 2007; Gemzell-Danielsson, 2010; Taylor et al.,
2014). When used very near to ovulation, LNG is much less effective
than when used earlier in the follicular phase, contributing to lower efﬁ-
cacy estimates of post-coital use during this time frame. Precoital use of
LNG is likely to be more effective at preventing pregnancy than post-
coital use as it may simultaneously affect both cervical mucus and delay
or arrest ovulation (Halpern et al., 2014).
There is some information regarding repeated use of LNGas EC in the
same menstrual cycle. A recent Cochrane review of repeated pericoital
hormonal contraceptive use identiﬁed 12 clinical trials conducted in
the 1970s and 1980s, including a total of 12 407 women who used the
prescribed method for a total of about 1033 woman-years (W-Y)
(Halpern et al., 2014). These women represented a broad cross
section of the female population in terms of age and reproductive
history. In each of these trials, women were instructed to take 0.75 mg
LNG immediately after (in most studies, within 1 h of) unprotected
sex. In most trials, the observed coital frequency was a mean of about
four times a month.
The Pearl Index (PI: number of pregnancies per 100 W-Y) in these
studies ranged from 0 to 18.6 pregnancies per 100 W-Y and a com-
bined ﬁgure was 5.1 pregnancies/100 W-Y (95% conﬁdence interval
[CI] 3.8, 6.7) (Halpern et al., 2014). The efﬁcacy of the method did
not seem to be consistently related to any particular characteristic of
the study population or to coital frequency. Overall, these data
suggest that the efﬁcacy of pericoital LNG was in the range of that of
other coital-dependent contraceptives like the condom (Trussell,
2009, 2011).
Themain side effects of pericoital use of 0.75 mg LNGwere abnormal
uterine bleeding, breast tenderness, dizziness, lower abdominal pain,
fatigue, headache, weight gain, irritability, weakness and loss of libido.
The incidence of these side effectswas not clearly related to the frequency
of tablet intake. Most subjects were satisﬁed with the method (Halpern
et al., 2014). However, the PI was high when LNG 0.75 mg was used,
which is the main reason why 1.5 mg was chosen for the present study.
Despite the body of evidence about the use of LNG pill as EC, the
potential of pericoital useof LNG1.5 mgasaprimarymeansof contracep-
tion has not yet been established. Consequently, the objectives of
this proof of concept study were to evaluate the efﬁcacy and safety of
LNG 1.5 mg among women who expected to have sex on 1–6 days
per month and who are relying on the study regimen as their primary
method of contraception.
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Materials andMethods
Study participants
This was a prospective, open-label, single-arm, multicentre Phase III trial
study with women who have infrequent coitus (up to 6 days a month). The
participants were enrolled at the Human Reproduction Unit, Department
of Obstetrics and Gynaecology, University of Campinas, Campinas, Brazil;
the Department of Obstetrics and Gynaecology, Siriraj Hospital, Mahidol
University, Bangkok, Thailand; the Department of Obstetrics andGynaecol-
ogy, National University Hospital, Singapore and the Department of
Obstetrics and Gynaecology, Albert Szent-Gyorgyi Medical Centre, Univer-
sity of Szeged, Szeged, Hungary. The study was approved by the UNDP/
UNFPA/UNICEF/World Health Organization (WHO)/World Bank
Special Programme of Research, Development and Research Training in
Human Reproduction (HRP) Research Project Review Panel (RP2), the
WHO Ethics Review Committee, and by the local ethics review board at
each country site.
The study enrolled non-pregnant healthy fertile women of reproductive
age (18–45 years) who had sex on between 1 and 6 days a month, were at
low risk for sexually transmitted infections (STIs), were willing to use LNG
1.5 mg tablets as their primary contraceptivemethod, wanted to avoid preg-
nancy for at least the next 6.5months after enrolment, werewilling to accept
an uncertain risk of pregnancy during the study, and understood that the risk
of pregnancy on this methodwould be higher than other hormonal methods
of contraception.
The exclusion criteria included being not at risk of pregnancy (currently
pregnant, breastfeeding, recently post-partum, using an intrauterine device
or had female or male sterilization); having a breast mass; or with contraindi-
cations to hormonal contraceptive use, and previous participation in the
study or any other current medical research. The informed consent form,
signed by all participants, included the nature, beneﬁts and risk and instruc-
tions for use: ‘Take one tablet every time you have sex, preferably before
or as soon as possible after the sex act. You have up to 24 h before or
after sex to take the tablet. Do not take more than one tablet in any 24-h
period’. The women were counselled to take a second tablet if she
vomitedwithin 1 h after taking a study tablet. If she failed to follow the instruc-
tions (missed an indicated tablet), shewas asked to contact the study site for
advice about using EC pills. Tablets were provided in blister packages of 7
(provided by Delpharm Lille S.A.S; Lys-lez-Lannoy Cedex, France).
Women were advised to use condoms if needed to protect against STI or
human immunodeﬁciency virus. Furthermore, the women were instructed
to maintain a paper diary, on which she recorded date and time for every
coital act and ingestion of the study tablet, use of other contraceptive
methods such as condoms, and occurrence of vaginal bleeding or spotting.
Participants were instructed to bring the diary with them during follow-up
visits.
Procedures
Each subject had an enrolment visit and three follow-up visits at 2.5, 4.5 and
6.5months after admission. After assessment of eligibility, baseline data (in-
cluding weight, blood pressure [BP] and haemoglobin [Hb]) level were col-
lected, and each participant was provided with the study medication and
instructions on use. At each follow-up visit, data about use of the study
product and other contraceptives, vaginal bleeding, and adverse events
(AE) were collected and a BP check and urine pregnancy test was per-
formed. At the 2.5-month and ﬁnal visit at 6.5 months, acceptability ques-
tions were administered. At the ﬁnal visit, weight and Hb levels were
rechecked. The site investigator team contacted each subject by telephone
Figure1 Participant ﬂowchart for the study. *Twoparticipantswith pregnancy conception datedprior to enrolment (Singapore ID3048, Brazil ID4305).
†Use of prohibited contraception (n ¼ 2: Hungary, Brazil), stopped study pill (n ¼ 2: Hungary, Thailand), health reasons (n ¼ 1: Hungary).
ITT Popn, intention to treat population; EV Popn, evaluable populations; Primary EV, primary evaluable population; User Popn, population.
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between follow-up visits to ascertain the result of the home pregnancy test
(performed each month where there was no in-clinic visit), to ask about
continued use of the product, and to ensure that the subject had sufﬁcient
supply to last until the next scheduled visit. The site investigator team
entered data into an electronic database and transmitted it electronically
to theWHO for analysis. Pregnancies were ascertained by urine pregnancy
tests at each visit, by home pregnancy tests between visits, and by subject
self-report. Those with a positive urine pregnancy test had an ultrasound
to conﬁrm the pregnancy usually at 5–8 weeks gestation.
Data collection forms were reviewed for accuracy and completeness
bystudystaff in-country.Dataweredouble-entered intotheOpenClinicaweb-
baseddatamanagement systemversion3.1.3 (AkazaResearch,Waltham,MA,
USA). Validation checks and regular review of missing values, outliers, incon-
sistencies, and other errors were conducted.
Statistical analyses
All statistical analyses were performed using the SAS system for Windows.
Release 9.3. 2011. (SAS Institute, Cary, NC, USA).
As aproof-of-concept study, theprotocol established toenrol 300women
into the study.Theprimaryefﬁcacyanalysis estimated thePI during sole useof
the studymedication amongwomen at age of≤35 years. This analysiswould
censor each subject’s data on the date when she stopped considering the
study product to be her primary contraceptive method and would exclude
months in which a woman used any other method of contraception (such
as condoms). Additionally, efﬁcacy analyses estimated the PI during typical
and perfect use of the product, and life-table analysis of pregnancy rates
through 6 months of sole, typical and perfect use of the study product.
Perfect use analysis excluded months during which the study product was
not used according to instructions and typical use analysis included study
months in which a subject used any other method of contraception in
addition to the study pill.
Analogous analyses in the entire enrolled population and in speciﬁed sub-
groups were also conducted, with the following deﬁned population groups:
(i) Intent-to-treat population (ITT); referring to all subjects who were
enrolled and provided study medication at the enrolment visit; (ii) Evaluable
Population; referring to all subjects in the ITT population who provide any
follow-up data except those who had admission criteria violations that may
detract from an accurate analysis of efﬁcacy; (iii) Primary Evaluable Popula-
tion; referring to a subgroup of the Evaluable Population who were age of
≤35 years and (iv) User Population; including all subjects in the ITT popula-
tion who used the study method at least once.
Safety analyses estimated the proportion of all subjects, including thoseover
35 years old,who had various safety outcomes of interest, including changes in
vaginal bleeding parameters from baseline and other adverse events. Bleeding
patterns were analysed according to the terminology proposed by theWHO
(Belsey et al., 1986; WHO, 1989) for users of progestin-only methods in
90-day reference periods as: Amenorrhoea: deﬁned as no bleeding during the
90-days reference period; Infrequent bleeding: fewer than 3 bleeding episodes;
Frequent bleeding: more than 5 bleeding episodes; Irregular bleeding: range of
bleeding-free intervals exceeding 17 days; Prolonged bleeding: 1 ormore bleed-
ing episodes lasting 14 days or more; light bleeding or spotting: only light days;
mediumbleeding: at least 1 dayofmediumbleedingornodayof heavybleeding;
heavy bleeding: at least oneor 2 days of heavybleeding,with any numberof light
and medium days; very heavy bleeding: 3 or more days of heavy bleeding, with
any number of light and medium days; None of the above: a ‘normal’ bleeding
pattern.
Anaemiawas categorizedasmild (10–11 g/dlHb),moderate (8–,10 g/dl
Hbor a decrease from baseline of 2–4 g/dl) or severe (,8 g/dl Hb or a de-
crease frombaseline of≥4 g/dl) and reported using frequencies andpercen-
tages. Bleeding patterns and adherence were summarized according to the
information captured in the diaries. The diary information was checked by
........................................................................................
Table I Selected baseline characteristics of the
participants in a study to evaluate the efﬁcacy, safety and
acceptability of pericoital oral contraception using
levonorgestrel 1.5 mg.
Characteristics N (%)
Race
White 115 (34.8)
Black 23 (7.0)
Biracial 32 (9.7)
Asian 160 (48.5)
Highest educational level
Never attended nor completed primary education 7 (2.1)
Primary 26 (7.9)
Secondary 131 (36.7)
Higher than secondary 166 (50.3)
Marital status
Married or with life partner 258 (78.2)
Separated/divorced/widowed 8 (2.4)
Single 64 (19.4)
Number of live births (among those ever pregnant)
None 21 (8.4)
1 124 (49.4)
2 71 (28.3)
3 or more 35 (13.9)
Ever used contraceptives
Yes 307 (93.0)
Contraceptive methods used
Oral contraceptive pills 243 (79.2)
Male condom 274 (89.3)
Injectables 99 (32.2)
Copper IUD or levonorgestrel intra-uterine system 90 (29.3)
Emergency contraceptive pills 87 (28.3)
Contraceptive ring or patch 17 (5.5)
Implants 15 (4.9)
Vaginal spermicide 8 (2.6)
Withdrawal 119 (38.8)
BMI, kg/m2
Underweight (,18.5) 19 (5.8)
Normal (18.5 to ,25.0) 169 (51.2)
Overweight (25.0 to ,30.0) 95 (28.8)
Obese (≥30.0) 47 (14.2)
Characteristics
Age, years
Mean (SD) 32.4 (6.8)
Range 18.0–45.4
Frequency of coitus, days in the past month
Mean (SD) 4.1 (1.7)
Median (IR) 4.0 (3.0, 6.0)
Weight, kg
Mean (SD) 64.1 (14.1)
Median (IR) 62.0 (55.0, 72.0)
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staff in the presence of the woman against the relevant info in the follow-up
form.
Acceptability analyses fromall subjects included calculations of discontinu-
ation rate by reason, as well as summaries of responses to the acceptability
questions. Future contraceptive desires were assessed during 2.5 month
and 6.5 month visits or at early discontinuation.
Results
The number of women assessed for eligibility, the number enrolled and
the different analyses performed are shown in Fig. 1. Almost 50% of the
subjects were Asian, and between 46 and 67% of the women were aged
25–35 years old. Baseline socio-demographic characteristics of the
participants are shown in Table I.
Ten conﬁrmed pregnancies occurred among the evaluable population
during 141.9 W-Y of observation. The incidence per 100W-Y (95% CI)
was 7.1 (3.8; 13.1) for typical use and 7.5 (4.0; 13.9) during sole use in
the evaluable population. In the primary evaluable population (less than
35 years old) wherein there were nine pregnancies, the rate was 10.3
(5.4; 19.9) pregnancies per 100 W-Y of typical use, and 11.0 (5.7; 13.1)
pregnancies per 100 W-Y of sole use (Table II). In addition, almost 80%
of the participants returned for the scheduled three visits and almost an
equal proportion of women completed the study. The lost to follow-up
was only 1.5% of the ITT population (Table III). The distribution of the
pill intake by month of follow-up ranged from a mean of 4.2–6.9 in the
ﬁrst month to 4.3–6.2 by the sixth month of follow-up. The pill intake
during the other months of observation was within the same range.
Furthermore, no relationship was observed between the pregnancy rate
and the frequency of pill intake per month of observation.
Regarding adverse events, most of those reported were mild and the
most common were headache, nausea and abdominal and pelvic pain
(Table IV). These occurred more often among women who took 4–6
pills per month. There were two participants who had severe adverse
events, both assessed by the site investigators and authors to be not
related to pill intake: one woman was admitted for choledocholithiasis
for which she subsequently had surgery (last pill intake was 10 days
before diagnosis) and the other had a ruptured corpus luteum cyst
(last pill intake was 1 day before diagnosis).
......................................... ......................................... .........................................
.............................................................................................................................................................................................
Table II Contraceptive efﬁcacy according to category of use.
Typical use* Sole pill use** Perfect pill use***
Study
population
n Total number
of pregnancies
Total
W-Y
Incidence per 100
W-Y (95% CI)
Total
W-Y
Incidence per 100
W-Y (95% CI)
Total
W-Y
Incidence per 100
W-Y (95% CI)
Primary evaluable
Overall 204‡ 9† 87.10 10.3
(5.4, 19.9)
81.62 11.0
(5.7, 21.2)
81.14 11.1
(5.8, 21.3)
Hungary 32 2 13.02 15.4
(3.8, 61.4)
11.78 17.0
(4.2, 67.9)
11.78 17.0
(4.3, 67.9)
Thailand 61 2 29.24 6.8
(1.7, 27.4)
29.24 6.8
(1.7, 27.4)
29.24 6.8
(1.7, 27.4)
Singapore 49 0 23.23 – 20.86 – 20.82 –
Brazil 62 5 21.60 23.2
(9.6, 55.6)
19.74 25.3
(10.5, 60.9)
19.30 25.9
(10.8, 62.3)
Evaluable population
Overall 321† 10† 141.92 7.1
(3.8, 13.1)
133.70 7.5
(4.0, 13.9)
133.05 7.5
(4.0, 14.0)
Hungary 70 3 30.24 9.9
(3.2, 30.8)
28.79 10.4
(3.4, 32.3)
28.79 10.4
(3.4, 32.3)
Thailand 80 2 38.40 5.2
(1.3, 20.8)
38.31 5.2
(1.3, 20.9)
38.31 5.2
(1.3, 20.9)
Singapore 79 0 37.56 – 34.49 – 34.45 –
Brazil 92 5 35.73 14.0
(5.8, 33.6)
32.11 15.6
(6.5, 37.4)
31.50 15.9
(6.6, 38.1)
‡A total of four participants excluded from primary evaluable population: aged ≤35 years but pill not primary contraception method.
†A total of nine participants excluded: Two (2) who became pregnant before enrolment (discovered during follow-up) and seven others who did not initiate pill use/pill not primary
contraception method, it includes one woman who became pregnant at post-enrolment.
*Typical pill use considers total woman-years from admission to the date when participant stopped considering the study product to be her primary contraceptive method, and includes
months in which a subject used any other method of contraception.
**Sole pill use considers total woman-years from admission to the date when participant stopped considering the study product to be her primary contraceptive method, and excludes
months in which a subject used any other method of contraception.
***Perfect pill use considers total woman-years from admission to the datewhen participant stopped considering the study product to be her primary contraceptivemethod, and excludes
months in which (i) pill use not sole, (ii) .1 pill within 24 h and (iii) vaginal sex but no pill intake.
W-Y, Women-years; CI, conﬁdence interval.
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Vaginal bleeding patterns are presented in Fig. 2. The categories may
not be mutually exclusive, as frequency, regularity, days of bleeding and
volume are all considered in the description. In general, the women
experienced prolonged bleeding only during the intake of the ﬁrst 10
pills. Frequent bleeding did not change during the period of observation
and with the number of used pills. Furthermore, lighter bleeding periods
were observed and very heavy bleeding decreasedwith higher pill intake
through themonths of the study. Ratesof anaemiawere low in this popu-
lation group. Moderate anaemia (from 8 to 10 g/dl) decreased from 5
out of 330 women (1.5%) at baseline, to 2 out of 258 women (0.8%)
at ﬁnal study visit. There was only one case of severe anaemia, found
at the ﬁnal visit (0.4%) after taking a total of 24 pills over the full observa-
tion period.
Acceptability was assessed at the 2.5 and 6.5months visits. Most of the
women would use this method in the future if it was available and would
recommend it tootherwomen. Furthermore,we asked about reproduct-
ive intention to see if their responses correlated with how well they used
the study pills. A total of 12.1% of the women reported some sexual
intercourse without taking the pill (Table V).
There are additional analyses presented in the Supplementary
Tables. Supplementary Table S1 would show that there is no clear
pattern of pill intake per month of follow-up among the user popula-
tion that included women who took the tablet at least once.
Supplementary Table S2 would show the number of pregnancies by
the frequency of pill intake per menstrual cycle in the primary evalu-
able population. Supplementary Table S3 shows the percentage distri-
bution of most common side effects by the number of times LNG was
taken per month.
Discussion
Pericoital use of 1.5 LNG as a regular contraceptive method is effective,
with fewmild side effects andwith high acceptability. The observedpreg-
nancy rate is comparable to that reported for other coitally-dependant
contraceptive methods (Trussell, 2009, 2011).
Previous studies of pericoital use using 0.75 mg of LNG (which is half
the dose used in the present study) found similar or higher pregnancy
rates (Halpern et al., 2014; Taylor et al., 2014), which may be due to
the difference in LNG dose, the characteristics of women included, the
study sample size, or the difference in the number of sex acts per
month during the period of observation. Different contraceptives have
different characteristics that would ﬁt into the needs of the woman.
The use of LNG 1.5 mg as pericoital contraceptive would be less efﬁca-
cious than other modern methods taken continuously or are long acting
methods. Ideally LNG1.5 mgcanbeusedbywomenwhoarenot already
using contraception or are only using barrier methods.
.............................................................................................................................................................................................
Table III Self-reported adherence or compliance by the participants
Description ITT
(N 5 330)
Evaluable
(N5 328)
Primary
evaluable
(N5 208)
User
(N5 303)
Number of women completing 6.5 months of follow-up 258/330 (78.2) 258/328 (78.7) 152/208 (73.1) 255/303 (84.2)
Number of women who used study pill as their primary method for 183 days or
until pregnancy (if occurred ≤183 days)
323 321 204 303
Total number of woman-years using the study pill as the main contraceptive method 142.85 142.61 87.74 139.01
Total number of woman-years using only the study pill (study regimen)‡ 134.95 134.71 82.59 131.11
Number of participants with completed follow-up scheduled study visits, n (%)
1 visit 30/330 (9.1) 30/328 (9.1) 21/208 (10.1) 26/303 (8.6)
2 visits 10/330 (3.0) 10/328 (3.1) 10/208 (4.8) 10/303 (3.3)
3 visits 258/330 (78.2) 258/328 (78.7) 152/208 (73.1) 255/303 (84.1)
Number of participants who:
– Completed study, n (%)(Participant used studypill as theprimarymethod for up to at
least 183 days or became pregnant during product use before 183 days.)
270/323* (83.6) 268/321 (83.5) 161/204 (78.9) 266/303 (87.8)
– Discontinued early, n (%)(Participant discontinued use of study product as their
primary method before 183 days while not known to ever have become pregnant
during its use.)
48/323* (14.9) 48/321 (15.0) 38/204 (18.6) 36/303 (11.9)
– Lost to follow-up, n (%)(Participant neither completed 183 days follow-up nor
discontinued early (if ,183 days) and the time she stopped using the study pill as
primary method nor whether she became pregnant during its use is unknown.)
5*/323* (1.5) 5*/321 (1.5) 5*/204 (2.5) 1/303 (0.3)
*Seven (7) participants IDs 4185, 4264, 4328, 4376, 4449, 4463 & 4487 (all from Brazil site) were excluded from method discontinuation/pill use analysis, since available data show no
indication that their primary method of contraception was study pill nor that study pill was ever used during sex act. Of these, three (3) were lost to follow-up (: IDs 4185, 4449, 4463).
‡Six (6) participants commenced using study pills together with other types of contraception not included: Ids 1018 & 1098 (Hungary), 3071 & 3101 (Singapore), 4195 & 4502 (Brazil)—
excluded from person year estimation.
ITT, intent-to-treat population.
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Althoughdifferent studieswith theuseofLNG0.75 mgafterunprotected
sexual intercourse showed a PI from zero to 18.6 per 100 W-Y (Halpern
et al., 2014), the three larger multicentre studies with 915 participating
women presented a PI from 6.8 to 18.0 pregnancies per 100W-Y, with a
pooled PI of 8.9 per 100 W-Y (95% CI 5.1–14.4) (Bhattacharjee et al.,
1987; He et al., 1991; WHO, 2000; Halpern et al., 2014), which is slightly
lower than the PI for the primary efﬁcacy analysis (11.0) and only slightly
higher than the PI for the entire evaluable population in the present study.
The prior studies of postcoital LNG regimens had limitations. First,
many of the study reports are dated, brief and vague and many details
relating to the study procedures and ﬁndings are not included. Because
most of the studies were conducted before year 2000 (Halpern et al.,
2014), this problem does not appear to be remediable. Second, the
prior studies did not collect some data of interest, such as measures of
anaemia, which is an important safety consideration in use of a method
that could cause abnormal vaginal bleeding. Finally, the trials were con-
ducted with LNG 0.75 mg and the steroid was taken exclusively after
sexual intercourse. Data showing that ECs are more effective if taken
close to the time of sexual intercourse suggest that a regimen that can
be used either before or after intercourse may have the potential to
optimize contraceptive efﬁcacy (Piaggio et al., 2011). EC with LNG is
recommended using a single dose of 1.5 mg; it has similar efﬁcacy to
two doses of 0.75 mg taken 12 h apart, and the single-dose regimen
simpliﬁes the drug use without an increase in side effects (von Hertzen
et al., 2002; Dada et al., 2010).
A contraceptive pill which can be taken only when the woman has
sexual intercourse may have a number of advantages for women who
have sex infrequently. Many women have infrequent sex for many
reasons, including a partner who is not always at home, such as sailors,
military personnel and those in prison. Furthermore, it may reduce the
amount of steroid intake and it is private, which is important mainly
among adolescents. Additionally, this method could reduce the possibil-
ityof forgetting to takeapill, as it is takenclose to sexual intercourse itself.
Despite the fact that postcoital contraceptionwith oral LNGas EChas
been extensively evaluated in numerous studies and it is registered in
many countries, information about the pericoital EC use of 1.5 mg
LNG is scarce. The evidence for its repeated use, either as a regular
contraceptive or as EC, is limited, and especially on the perceived
higher rates of side effects and lower contraceptive effectiveness when
compared with other modern contraceptives (Bhattacharjee et al.,
1987; ACOG, 2012; WHO, 2012).
Regarding bleeding patterns, our results showed that the only one
which could be inconvenientwas frequent bleeding, whichwasobserved
through the entire period of the study and independent of the number of
pills the women takes. A previous study (Bhattacharjee et al., 1987)
assessed the side effects of postcoital LNG 0.75 mg used repeatedly
(mean+ SD 4.0+2.6 tablets) during one cycle. The overall effect of
LNG upon bleeding patterns—mainly cycle length—was insigniﬁcant;
however, intermenstrual bleeding or spotting was observed in 8.5% of
the treated cycles and 12.5% of the irregular cycles. Others did not
observe an association between cycle control and the number of pills
taken (Bhattacharjee et al., 1987; He et al., 1991).
The three reported serious adverse effects in this study were, in the
judgment of the investigators, not related to the study product.One par-
ticipant had cholelithiasis, and had a cholecystectomy, which were
reported as two adverse events. The other was a case of haemorrhagic
corpus luteum cyst, which was removed within the same day. The inci-
dence of side effects was low and these were in general mild and many
not related to the study pill, as described previously (Taylor et al.,
2014) and also not related to the number of pills taken (Supplementary
Table S3). Furthermore, the observed high acceptability is consistent
with previous reports which showed acceptability ranging from 49 to
81% (WHO, 2000; Taylor et al., 2014) and may indicate that side
effects were not very important to the participants.
There were methodological limitations in this study. This study was
designed as a basis for future trials, targeting a group of women who
have infrequent sex, in as many sites and countries as possible. In
some sites, recruitment and follow-up were efﬁcient; however, in the
site in Hungary, recruitment of study participants took more than 18
months.
In conclusion, this study showed that the regular use of LNG 1.5 mg
pericoitally in women who have infrequent sex is a safe strategy and, in
general, is a well-tolerated method of contraception for women. The
contraceptive efﬁcacy was higher than women who do not use contra-
ceptionandcomparable towomenwhousedcoitally-dependent contra-
ceptives. Theproportion ofwomenwhowill be eligible to use this kindof
contraception is not easy to estimate.However, reports have shown un-
intended pregnancies are almost 50% in different settings. Many of these
........................................................................................
Table IV Summary of adverse events (AE).
Characteristics N (%)
Study site
Brazil 48 (47.1)
Hungary 27 (26.5)
Singapore 3 (2.9)
Thailand 24 (23.5)
Degree of severity
Mild 79 (77.5)
Moderate 20 (19.6)
Severe 3 (2.9)
Relatedness
Probably related 42 (41.2)
Probably not related 60 (58.8)
Required participant to stop using the pill because of the AE
No 96 (94.1)
Yes 6 (5.9)
Outcome of the AE
Recovered without sequelae 89 (87.2)
Recovered without sequelae 2 (2.0)
Ongoing as of last visit 11 (10.8)
Most common AE (more than 3 reports)
Headache 15 (29.3)
Nausea 6 (16.3)
Abdominal and pelvic pain 6 (16.3)
Inﬂuenza 4 (10.9)
Acne vulgaris 3 (8.1)
Candidiasis 3 (8.1)
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womenmay not be using regular contraceptives because they have infre-
quent sex, as reported in theUSA (Herbenick et al., 2010). Pericoital use
(on demand, i.e. taken only when having sexual intercourse, or less
frequent but repeated use) of LNG 1.5 mg could help in the reduction
of unintended pregnancies and this research provides valuable informa-
tion about the repeated use.
Figure2 Frequency of irregular bleeding patterns per 90 day study period based on number of tablets taken: (A) prolonged vaginal bleeding (at least one
bleeding episode lasting 14 days or more during the reference period of 90 days); (B) frequent vaginal bleeding episodes (deﬁned as having more than ﬁve
bleeding episodes throughout the reference period of 90 days); (C) light vaginal bleeding episodes; (D) medium vaginal bleeding episodes (at least 1 day of
mediumwith anynumberof light bleedingdays recordedduring theepisode, andnodaysof heavybleeding); (E) heavy vaginal bleeding episodes (at least1or
2 days of heavy bleeding recorded, with any number of light and medium days, during the episode) and (F) very heavy vaginal bleeding episodes (three or
more days of heavy bleeding recorded during the episode, with any number of light and medium days).
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Figure 2 Continued.
.............................................................................................................................................................................................
Table V Acceptability indicators.
Questions At 2.5
months
N (%)
At 6.5
months
N (%)
If the study pills were shown to be effective for preventing pregnancy, and they were available outside the study, do you think
you might want to use them for contraception in the future?
No 11 (3.7) 3 (1.2)
Yes 275 (92.3) 247 (95.7)
Don’t know 12 (4.0) 8 (3.1)
If the study pills were shown to be effective would you recommend the study pills as a method of contraception for other
women?
No 5 (1.7) 1 (0.4)
Yes 286 (96.0) 252 (97.7)
Don’t know 7 (2.3) 5 (1.9)
Were there ever times when you had sex and did not use the study pills?
No 261 (87.6) 243 (94.2)
Yes 36 (12.1) 15 (5.8)
Don’t know 1 (0.3) 0 (0.0)
Do you want any (more) children ever in the future?
No 130 (43.6) 119 (46.1)
Yes 143 (48.0) 115 (44.6)
Don’t know 25 (8.4) 24 (9.3)
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Supplementary data
Supplementary data are available at http://humrep.oxfordjournals.org/.
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